6 research outputs found

    μ•„λ“œλ ˆλ‚ λ¦°μ„± B-수용체 μžκ·Ήμ— μ˜ν•œ 림프ꡬ λ‹¨λ°±μ˜ 인산화

    No full text
    μ˜ν•™κ³Ό/박사[영문] [ν•œκΈ€] λ‹¨λ°±μ˜ 가역적인 인산화과정이 μ„Έν¬μ˜ 생리적 μ΅œμ’…λ°˜μ‘μ„ λ§€κ°œν•˜κ±°λ‚˜ μˆ˜ν–‰ν•œλ‹€κ³  μ•Œλ € μ Έ μžˆλ‹€. κΈ€λΌμ΄μ½”μ  μ˜ ν•΄λ‹Ήλ°˜μ‘ λ“±μ˜ νƒ„μˆ˜ν™”λ¬ΌλŒ€μ‚¬, μ„Έν¬μ¦μ‹λ°˜μ‘, μ„Έν¬λ§‰μ—μ„œμ˜ 이온운 반 λ“±μ˜ μƒμ²΄λ°˜μ‘ 뿐 μ•„λ‹ˆλΌ λ©΄μ—­λ°˜μ‘κ³„μ—μ„œλ„ νŠΉμ •λ‹¨λ°±μ˜ 인산화가 μ‘°μ ˆμ„ ν•œλ‹€κ³  ν•œλ‹€. 각쒅 μ‘°μ§μ—μ„œ Ξ²μ•„λ“œλ ˆλ‚ λ¦°μ„± 효과의 약리적 νŠΉμ„±μ€ 잘 μ•Œλ €μ Έ 있으며 특히 림프ꡬ에 μ„œ Ξ²μˆ˜μš©μ²΄μ— μ˜ν•˜μ—¬ λ©΄μ—­ 및 μƒμ²΄μ˜ 항상성 μœ μ§€κ°€ μ‘°μ ˆλœλ‹€κ³  ν•œλ‹€. Ξ² μ•„λ“œλ ˆλ‚ λ¦°μ„± μˆ˜μš©μ²΄κ°€ 자극되면 GTP 결합단백을 ν†΅ν•˜μ—¬ adenylate cyclase ν™œμ„±μœΌλ‘œ cAMPκ°€ μƒμ„±λ˜κ³ , cAMPλŠ” cAMP μ˜μ‘΄μ„± kinase (A-kinase)λ₯Ό ν™œμ„±ν™”μ‹œν‚¨λ‹€. ν™œμ„±ν™”λœ A-kinaseλŠ” 단백을 인 μ‚°ν™” μ‹œν‚΄μœΌλ‘œμ¨ 인산화단백이 μ΅œμ’…μ μœΌλ‘œ λ°˜μ‘μ‘°μ ˆμ— κ΄€μ—¬ν•œλ‹€κ³  ν•œλ‹€. κ·ΈλŸ¬λ‚˜ 림프ꡬ에 μ„œ μ–΄λŠ νŠΉμ •λ‹¨λ°±μ΄ A-kinase에 μ˜ν•΄ ν™œμ„±ν™”λ˜μ–΄ λ°˜μ‘μ„ λ§€κ°œν•˜λŠ”μ§€μ— λŒ€ν•œ 체계적인 μ—° κ΅¬λŠ” λ˜μ–΄μžˆμ§€ μ•Šλ‹€. λ”°λΌμ„œ 이번 μ—°κ΅¬μ—μ„œλŠ” 흰μ₯μ˜ λ¦Όν”„κ΅¬μ—μ„œ Ξ²μ•„λ“œλ ˆλ‚ λ¦°μ„± 수용체ν₯뢄후에 λ‚˜νƒ€λ‚˜λŠ” 단백 인산화 양상을 κ΄€μ°°ν•˜κ³ , 쀑간과정을 μ κ²€ν•˜μ—¬ Ξ²μˆ˜μš©μ²΄μžκ·Ήν›„μ— A-kinase에 μ˜ν•˜μ—¬ μΈμ‚°ν™”λ˜λŠ” 특이 κΈ°μ§ˆλ‹¨λ°±μ„ 찾고자 ν•˜μ˜€λ‹€. μ‹€ν—˜ μž¬λ£Œλ‘œλŠ” 흰μ₯(Sprague-Dawley)의 동λ§₯혈의 림프ꡬλ₯Ό μ΄μš©ν•˜μ˜€κ³ , β수용체ν₯λΆ„ν›„ λ°˜μ‘μ˜ μΆœν˜„κΉŒμ§€μ˜ 쀑간단계λ₯Ό μΆ”κ΅¬ν•˜κΈ° μœ„ν•˜μ—¬ isoproterenol, propranolol, forskolin , cAMP 및 H-8을 μ‚¬μš©ν•˜μ˜€λ‹€. λΆ„λ¦¬λœ 림프ꡬλ₯Ό [(32)**P ] orthophosphate둜 ν‘œμ§€μ‹œν‚¨ ν›„ 림프ꡬλ₯Ό κ· μ§ˆν™”ν•œ ν›„ 원심 λΆ„λ¦¬ν•˜μ—¬ λ‹¨λ°±λΆ„νšμ„ μ–»κ³ , 이λ₯Ό NEPHGE와 SDS-PAGEλ₯Ό μ΄μš©ν•œ μ΄μ°¨μ›μ „κΈ°μ˜λ™λ²•μ„ μ΄μš©ν•˜ μ—¬ 단백을 λΆ„λ¦¬ν•œ ν›„ κ±΄μ‘°μ‹œν‚¨ gel을 μžκ°€λ°©μ‚¬κΈ°λ‘λ²•μœΌλ‘œ 인산화단백을 κ΄€μ°°ν•˜μ˜€λ‹€. ν•œνŽΈ 림프ꡬλ₯Ό 미리 κ· μ§ˆν™”μ‹œμΌœ λ§Œλ“  각 μ„Έν¬λΆ„νšŒμ—μ„œλ„ μ•½λ¬Όμ²˜λ¦¬ν›„ [Ξ³-(32)**P ]ATP둜 인산 ν™”μ‹œν‚¨ ν›„ λ™μΌν•œ λ°©λ²•μœΌλ‘œ 인산화 단백을 κ΄€μ°°ν•¨μœΌλ‘œμ¨ μ•žμ—μ„œ 얻어진 인산화단백이 μ„Έ 포의 μ–΄λŠ λΆ„νšμ— μœ„μΉ˜ν•˜λŠ”κ°€λ₯Ό ν™•μΈν•˜μ˜€λ‹€. μ‹€ν—˜κ²°κ³ΌλŠ” λ‹€μŒκ³Ό κ°™λ‹€. 1. Isoproterenol (10**-5 M)은 흰μ₯ 림프ꡬ외 μ—¬λŸ¬ 단백을 인산화 ν•˜μ˜€μœΌλ©°, 그쀑 λΆ„ μžλŸ‰ 44kD λ“±μ „μœ„μ  6.3(44kD/6.3) λ‹¨λ°±μ˜ 인산화가 λ‚˜νƒ€λ‚¬λ‹€. 2. λ¦Όν”„κ΅¬μ˜ 44kD/6.3 λ‹¨λ°±μ˜ μΈμ‚°ν™”λŠ” propranolol 10**-5 M μ „μ²˜μΉ˜μ— μ˜ν•˜μ—¬ μ–΅μ œλ˜ μ—ˆλ‹€. 3. 44kD/6.3단백은 forskolin에 μ˜ν•˜μ—¬ λ†λ„μ˜μ‘΄μ μœΌλ‘œ 인산화정도가 μ¦κ°€ν•˜μ˜€λ‹€. 4. 림프ꡬ κ· μ§ˆμ•‘μ˜ 세포막 λΆ„νšμ— cAMPλ₯Ό μ²¨κ°€ν•˜μ˜€μ„ λ•Œ 44kD/6.3 λ‹¨λ°±μ˜ 인산화가 유 λ°œλ˜μ—ˆλ‹€. 5. 44kD/6.3 λ‹¨λ°±μ˜ μΈμ‚°ν™”λŠ” A-kinase μ–΅μ œμž¬μΈ H-8에 μ˜ν•˜μ—¬ 인산화가 μ–΅μ œλ˜μ—ˆλ‹€. 6. 44kD/6.3 단백은 세포막 λΆ„νšμ—μ„œλŠ” κ΄€μ°°λ˜μ—ˆμœΌλ‚˜, μ„Έν¬μ§ˆλΆ„νšμ—μ„œλŠ” κ΄€μ°°λ˜μ§€ μ•Šμ•˜ λ‹€. μ΄μƒμ˜ μ‹€ν—˜κ²°κ³Όλ‘œ 보아 흰μ₯ 림프ꡬ 단백쀑 λΆ„μžλŸ‰ 44kD, λ“±μ „μœ„μ  6.3의 단백은 β수 용체 자극, adenylate cyclase ν™œμ„±ν™”, cAMP 생성 및 A-kinase ν™œμ„±ν™”μ— μ˜ν•˜μ—¬ μΈμ‚°ν™”λ˜ λŠ” λ‹¨λ°±μž„μ„ μ•Œ 수 μžˆμ—ˆμœΌλ©°. 이 λ‹¨λ°±μ˜ 인산화가 Ξ²μˆ˜μš©μ²΄μžκ·Ήμ— μ˜ν•œ 림프ꡬ κΈ°λŠ₯변동 에 κ΄€μ—¬ν•  κ²ƒμœΌλ‘œ μΆ”μΈ‘λœλ‹€. Protein Phosphorylation in Murine Peripheral Lymphocytes by Ξ² Adrenoceptor Stimulation De Yeun Oh Deparment of Medical Science The Graduate School, Yonsei University (Directed by Associate Prof, Young Soo Ahn. M.D.) Reversible protein phosphorylation has been known as an important biological mechanism of cellular regulation such as carbohydrate metabolism, cell proliferation, ion transport through cell membrane and also in immunologic system. Beta adrenergic stimulation causes activation of adenylate cyclase and subsequent accumulation of intracellular cyclic adenosine monophosphate (cAMP) and activation of cAMP-dependent protein kinase (A-kinase). Lymphocytes possess Ξ² adrenoceptors on their plasma membranes and stimulation of Ξ² adrenoceptor causes inhibition of antibody production, lymphocyte proliferation and T cell mediated cytolysis. Specific substrate protein for A-kinase is thought to be a final mediator for those cellular responses. In this study, therefore, it was attempted to characterize the substrate protein for the A-kinase after Ξ² receptor stimulation in murine peripheral lymphocytes, Rat peripheral lymphocytes were isolated by centrifugation with Histopaque and incubated with isoproterenol, propranolol, forskolin, cAMP or H-8. Proteins were labelled with [(32)**P ] orthophosphate for the intact lymphocyte or [Ξ³-(32)**P ] ATP for the lymphocyte homogenate. The proteins were separated by means of two dimensional gel electrophoresis using non-equilibrium pH gradient electrophoresis and sodium dodecyl sulphate-polyacrylamide gel electrophoresis. Gels were dried and phosphorylated proteins were observed by autoradiogrhphy. Results obtained were as follows; 1. Beta adrenergic stimulation of the lymphocyte with isoproterenol (10**-5M ) caused intense phosphorylation of a protein having 44 kD mol wt. and pl 6.3 (44 kD/6.3) which was not observed in the absence of isoproterenol stimulation. 2. Phosphorylation of 44kD/6.3 protein induced by isoproterenol was inhibited by the pretreatment with propranolol (10**-5M ). 3. Activation of adenylate cyclase by forskolin caused a phospherylation of the 44 kD/6.3 protein dose-dependently, 4. The 44 kD/6.3 protein was phosphorylated by the addition of cAMP in the lymphocyte homogenate, 5. The phosphorylation of the 44 kD/6.3 protein was selectively inhibited by H-8. 6. The 44 kD/6.3 protein was present in lymphocyte membrane fraction but not in cytosolic fraction. These results suggest that the 44 kD/6.3 protein may be the substrate protein phosphorylated by Ξ²-adrenergic stimulation and the phosphorylation of this protein would be related to the functional changes in rat lymphocytes by Ξ²-adrenergic stimulation.restrictio

    κ΅¬μ„œμ˜ CT26 μ„ μ•” λͺ¨λΈμ—μ„œ μ’…μ–‘μ˜ 진행에 λ”°λ₯Έ λ©΄μ—­μ§€ν‘œμ˜ λ³€ν™”

    No full text
    ν•™μœ„λ…Όλ¬Έ(박사)--μ„œμšΈλŒ€ν•™κ΅ λŒ€ν•™μ› :μ˜ν•™κ³Ό 내과학전곡,2005.Docto

    μ €μœ„λ„ MALTν˜• 림프쒅을 μ œμ™Έν•œ μ›λ°œμ„± μœ„μž₯κ΄€ λ¦Όν”„μ’…μ—μ„œ 초치료둜 μ‚¬μš©λœ ν•­μ•”ν™”ν•™μš”λ²•μ˜ 효과

    No full text
    Thesis (master`s)--μ„œμšΈλŒ€ν•™κ΅ λŒ€ν•™μ› :μ˜ν•™κ³Ό 내과학전곡,2002.Maste

    Motor Berve Conduction Velocity in Untreated Maturity-Onset Diabetes

    No full text
    μ˜ν•™κ³Ό/석사[영문] [ν•œκΈ€] 신경쑰직은 ν¬λ„λ‹Ήμ˜ 세포내 νˆ¬κ³Όμ— μΈμŠλ¦°μ„ ν•„μš”λ‘œ ν•˜μ§€ μ•ŠμœΌλ©° λ”°λΌμ„œ κ³ ν˜ˆλ‹Ήμ΄ 지 속될 경우 μ‹ κ²½μ„Έν¬λ‚΄μ˜ 포도당 및 κ·Έ λŒ€μ‚¬μ‚°λ¬Ό 농도가 λ†’μ•„μ Έμ„œ μ‹ κ²½μ„Έν¬μ˜ 퇴행성 λ³€ν™” κ°€ μ΄ˆλž˜λœλ‹€. λ³Έ μ—°κ΅¬μ—μ„œλŠ” λ‹Ήλ‡¨λ³‘ν™˜μžμ—μ„œ κ³ ν˜ˆλ‹Ήμ΄ 신경병변에 λ―ΈμΉ˜λŠ” 영ν–₯을 κ΄€μ°°ν•˜κΈ° μœ„ν•˜μ—¬ 30 예의 λ‹Ήλ‡¨λ³‘ν™˜μž 및 15예의 μ •μƒλŒ€μ‘°κ΅°μ—μ„œ μš΄λ™μ‹ κ²½μ „λ„μ†λ„λ₯Ό μΈ‘μ •ν•˜μ—¬ λ‹€μŒκ³Ό 같은 κ²° κ³Όλ₯Ό μ–»μ—ˆλ‹€. 1. λ‹Ήλ‡¨λ³‘ν™˜μžμ˜ μš΄λ™μ‹ κ²½μ „λ„μ†λ„λŠ” 정상인에 λΉ„ν•΄ 의의있게 κ°μ†Œλ˜μ—ˆλ‹€. 2. λ‹Ήλ‡¨λ³‘ν™˜μžμ—μ„œ μš΄λ™μ‹ κ²½μ „λ„μ†λ„λŠ” κ³΅λ³΅μ‹œ ν˜ˆλ‹ΉλŸ‰κ³Ό μ—­λΉ„λ‘€ 관계λ₯Ό λ‚˜νƒ€λ‚΄μ—ˆλ‹€. 3. λ‹Ήλ‡¨λ³‘ν™˜μžμ—μ„œ μš΄λ™μ‹ κ²½μ „λ„μ†λ„μ™€ λ‹Ήν™”ν˜ˆμƒ‰μ†Œ μ‚¬μ΄μ—λŠ” μœ μ˜ν•œ 상관관계가 μ—†μ—ˆλ‹€ . 4. ν™˜μžμ˜ μ—°λ Ή 및 당뇨병 μ΄ν™˜κΈ°κ°„κ³Ό μš΄λ™μ‹ κ²½μ „λ„μ†λ„ μ‚¬μ΄μ—λŠ” μœ μ˜ν•œ 상관관계가 μ—†μ—ˆλ‹€. μ΄μƒμ˜ μ„±μ μœΌλ‘œ 보아 당뇨병성 및 λ§μ΄ˆμ‹ κ²½μ—Όμ€ ν˜ˆλ‹Ήκ³Ό λ°€μ ‘ν•œ 관계λ₯Ό 가지고 μžˆλ‹€κ³  보며 ν˜ˆλ‹ΉμΉ˜μ˜ 지속적인 쑰절둜 μ‹ κ²½κΈ°λŠ₯은 보쑴 내지 ν˜Έμ „μ‹œν‚¬ 수 μžˆλ‹€κ³  μƒκ°λœλ‹€. Motor Nerve Conduction Velocity in Untreated Maturity-Onset Diabetes Do Yeun Oh Department of Medical Science The Graduate School Yonsei University (Directed by Prof. Kyung Hwan Kim, M.D.) Peripheral neuropathy is a frequent and often disabling complication of diabetes mellitus. Abnormalities of neural function in diabetes, such as slowed nerve conduction, may be related to the metabolic derangement in this disease, but the role of metabolic abnormalities in the development of diabetic neuropathy is controversial. To investigate the influence of hyperglycemia on nerve concution, conduction velocities of median, peroneal and tibial nerve were measured in 30 untreated maturity-onset diabetic patients and 15 normal control subjects. The results are as follows; 1. The motor nerve conduction velocities of median, peroneal, and tibial nerves were significantly slower in diabetics than normal. 2. Motor conduction velocity was inversely correlated with levels of fasting plasma glucose in diabetics. 3. Levels of glycosylated hemoglobin, an index of long-term glycemia, were not correlated with motor nerve conduction velocity. 4. Age and duration of diabetes were not related to the motor nerve conduction velocity. Theae findings suggest that the degree of hyperglycemia contributes to the slowing of motor nerve conduction velocity in untreated maturity-onset diabetes, but further studies are needed to clarify the relation with glycosylated hemoglobin and nerve conduction velocity diabetes.restrictio

    μ Šμ€ μ—¬μ„±μ˜ μœ λ°©μ— λ°œμƒν•œ μ›λ°œμ„± ν™œλ§‰ μœ‘μ’… 1예

    No full text
    ν™œλ§‰ μœ‘μ’…μ€ 주둜 κ΄€μ ˆ μ£Όμœ„ 쑰직에 ν˜Έλ°œν•˜λŠ” μ•…μ„± 쒅양이닀. μ’…μ’… κ΄€μ ˆ μ΄μ™Έμ˜ λ‹€λ₯Έ λΆ€μœ„μ— λ°œμƒν•˜λŠ” κ²½μš°λ„ λ³΄κ³ λ˜μ–΄μžˆλŠ”λ°, μ›λ°œμ„± 유방 ν™œλ§‰ μœ‘μ’…μ€ μ„Έκ³„μ μœΌλ‘œλ„ 보고된 μ˜ˆκ°€ λ“œλ¬Όλ‹€. λ³Έ μ¦λ‘€λŠ” μ›λ°œμ„± 유방 ν™œλ§‰ μœ‘μ’…μœΌλ‘œ μ§„λ‹¨λœ 15μ„Έ μ—¬μž ν™˜μžμ˜ 1μ˜ˆμ΄λ‹€. 진단 ν›„ 유방 쒅괴에 λŒ€ν•œ κ΄‘λ²”μœ„ μ ˆμ œμˆ μ„ μ‹œν–‰ν•˜μ˜€μœΌλ‚˜ 9κ°œμ›” ν›„ κ΅­μ†Œ μž¬λ°œν•˜μ˜€κ³ , 이에 재발 λΆ€μœ„μ— λŒ€ν•œ κ΄‘λ²”μœ„ μ ˆμ œμˆ μ„ λ‹€μ‹œ μ‹œν–‰ν•˜μ˜€λ‹€. κ·ΈλŸ¬λ‚˜, 27κ°œμ›” ν›„ 폐의 μš°μƒμ—½μ— 고립성 폐 전이가 λ°œκ²¬λ˜μ—ˆλ‹€. 이에 폐 병변에 λŒ€ν•œ 절제술 및 고식적 ν™”ν•™μš”λ²•μœΌλ‘œ doxorubicin 및 ifosfamide의 병합 ν™”ν•™μš”λ²•μ„ μ‹œν–‰ν•˜μ˜€λ‹€. ν˜„μž¬ ν•­μ•”ν™”ν•™μš”λ²• μ’…λ£Œ ν›„ 28κ°œμ›”μ§Έ 재발의 증거 없이 κ²½κ³Όκ΄€μ°° 쀑이닀. 이에 μ €μžλ“€μ€ λ³Έ 증둀λ₯Ό λ¬Έν—Œκ³ μ°°κ³Ό ν•¨κ»˜ λ³΄κ³ ν•˜λŠ” 바이닀

    The Impact of Primary Tumor Resection on the Survival of Patients with Stage IV Breast Cancer

    No full text
    Purpose The main treatment for stage IV breast cancer is currently systemic therapy. Surgical resection of the primary tumor is usually done for treating the tumor-related complications Recent studies have suggested that surgery may improve the long-term survival of stage IV breast cancer patients We evaluated the impact of the primary surgical resection site on the survival of stage IV breast cancer patients. Methods We reviewed the records of the stage IV breast cancer patients who were treated at Seoul University Hospital between April 1992 and December 2007 The tumor and clinical characteristics, the type of treatments and the overall survival were compared between the surgically versus nonsurgically treated patients. Results. Of the 198 identified patients, 110 (55 8%) received surgical excision of their primary tumor and 88 (44 2%) did not The mean survival was 67 months vs. 42 months for the surgically treated patients vs the patients without surgery, respectively (p=0 0287) On a multivariate analysis with using the Cox model and after adjusting for the estrogen receptor status, visceral metastases, the number of metastatic sites and trastuzumab treatment, surgery was an independent factor for improved survival (hazard ratio, 0.55; 95% confidence interval, 0.31-0.97; p=0.041). Conclusion Surgical resection of the primary tumor in stage IV breast cancer patients was independently associated with improved survival. Randomized prospective trials are needed to firmly recommend surgical resection of the primary tumor in stage IV breast cancer patientsλ³Έ μ—°κ΅¬λŠ” 폐암, μœ λ°©μ•”/λ‚œμ†Œμ•” μœ μ „μ²΄ μ—°κ΅¬μ„Όν„°μ˜ 연ꡬ비λ₯Ό 지원받아 μˆ˜ν–‰ λ˜μ—ˆμŒ(01-PJ3-PG6-01GN07-0004).Bafford AC, 2009, BREAST CANCER RES TR, V115, P7, DOI 10.1007/s10549-008-0101-7Blanchard DK, 2008, ANN SURG, V247, P732, DOI 10.1097/SLA.0b013e3181656d32*KOR BREAST CANC S, 2008, BREAST CANC FACTS FI, V1, P5Fields RC, 2007, ANN SURG ONCOL, V14, P3345, DOI 10.1245/s10434-007-9527-0Gnerlich J, 2007, ANN SURG ONCOL, V14, P2187, DOI 10.1245/s10434-007-9438-0Rapiti E, 2006, J CLIN ONCOL, V24, P2743, DOI 10.1200/JCO.2005.04.2226Morrow M, 2006, J CLIN ONCOL, V24, P2694, DOI 10.1200/JCO.2006.05.9824Babiera GV, 2006, ANN SURG ONCOL, V13, P776, DOI 10.1245/ASO.2006.03.033Hotta T, 2006, ANTICANCER RES, V26, P1377Abe O, 2005, LANCET, V366, P2087Andre F, 2004, J CLIN ONCOL, V22, P3302, DOI 10.1200/JCO.2004.08.095Giordano SH, 2004, CANCER, V100, P44, DOI 10.1002/cncr.11859Khan SA, 2002, SURGERY, V132, P620, DOI 10.1067/msy.2002.127544Flanigan RC, 2001, NEW ENGL J MED, V345, P1655Demicheli R, 2001, BRIT J CANCER, V85, P490Dauplat J, 2000, SEMIN SURG ONCOL, V19, P42Overgaard M, 1999, SEMIN RADIAT ONCOL, V9, P292DOGHETTO GB, 1999, AM SURGEON, V65, P352BLAND KI, 1998, BREAST COMPREHENSIVE, V2Ragaz J, 1997, NEW ENGL J MED, V337, P956OREILLY MS, 1994, CELL, V79, P315FISHER B, 1989, CANCER RES, V49, P1996*NAT CANC I, BREAST CANC TREATM P
    corecore